surmount-1 tirzepatide non-diabetic obesity weight loss In the trial (published in NEJM in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor surmount-1 surmount-1 trial tirzepatide non-diabetic obesity

Factors That Influence Weight Loss Results with Semaglutide The major factors that influence weight loss results with semaglutide include: Individual Factors An individuals starting age, sex, weight and body composition can influence the weight loss results with semaglutide

Available from: Wittich CM, Burkle CM, Lanier WL (2012) Ten common questions (and their answers) about off-label drug use

International journal of general medicine , 4 , 105113

[5] [11] Clinical trials have demonstrated significant weight loss with these medicationstypically 15% with semaglutide 2.4mg (Wegovy) and 5-8% with liraglutide 3.0mg (Saxenda) over 68 weekswhen used alongside dietary changes and physical activity advice